title: [Reinduction of paclitaxel therapy after a successfully treated hypersensitivity reaction].
abstract: BACKGROUND
  Paclitaxel containing chemotherapy is considered to be the first-line adjuvant treatment of epithelial ovarian cancers. Hypersensitive reaction is its most serious side effect including hypotension, respiratory distress, extensive urticaria or an intense cardiotoxicity. Due to these signs several physicians abandon of the otherwise hopeful chemotherapy.
  
  
  OBJECTIVE
  Having ceased the hypersensitive reaction one could successfully re-induct paclitaxel therapy after a repeated premedication course.
  
  
  METHODS
  A slow paclitaxel infusion rate with a 1/20 dose of the original concentration was administered for reinduction therapy when the patient became symptom-free after treatment with steroid and antihistamines.
  
  
  RESULTS
  Paclitaxel treatment was uneventfully instituted after reinduction as hypersensitivity has not been developed again.
  
  
  CONCLUSIONS
  According to the authors in case of hypersensitive reaction you need not abandon the otherwise effective paclitaxel treatment: it is worthy to institute the reinduction therapy.
authors.affiliation: Országos Onkológiai Intézet, Nógyógyászati Onkológiai Osztálya, Budapest. lehoczky@oncol.hu
authors.forename: Ottó
authors.initials: O
authors.lastname: Lehoczky
authors.forename: Andrea
authors.initials: A
authors.lastname: Bagaméri
authors.forename: Tamás
authors.initials: T
authors.lastname: Pulay
mesh_terms: D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology / Q000628:therapy; D004342:Drug Hypersensitivity / Q000209:etiology* / Q000628:therapy*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel